The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

The most advanced molecules in its pipeline target the IC proteins CD47, a ligand of signal-regulatory protein-α (SIRPα), and PD-L1, a ligand ... as well as bispecific antibody drug candidates.

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Novartis, meanwhile, handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million upfront for an option on the drug. Like PD-1/PD-L1, TIGIT is thought to ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high ... for the Fc-silent anti-TIGIT antibody domvanalimab ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab ...

Clinical Data shows that Q-1802 has significant anti-tumor activity. Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific ...